Technical Analysis for PRTC - PureTech Health plc

Grade Last Price % Change Price Change
B 52.01 -10.33% -2.99
PRTC closed up 12.16 percent on Friday, March 5, 2021, on 1.25 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Up
Historical PRTC trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish 12.16%
1,2,3 Pullback Bullish Bullish Swing Setup 12.16%
Narrow Range Bar Range Contraction 12.16%
Older End-of-Day Signals for PRTC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Gap Down Partially Closed 34 minutes ago
Gapped Down (Full) 34 minutes ago
3x Volume Pace 34 minutes ago
2x Volume Pace 34 minutes ago
1.5x Volume Pace 34 minutes ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

PureTech Health plc Description

PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for intractable cancers, lymphatic and gastrointestinal, central nervous system disorders, and inflammatory and immunological diseases in the United States. The company offers KarXT targeting muscarinic cholinergic receptors to treat schizophrenia and dementia-related psychosis, as well as pain; a superabsorbent hydrogel technology platform to treat excess weight and other chronic diseases related to the gastrointestinal pathways; a digital therapeutics to treat cognitive dysfunction associated with neurology and psychiatry conditions; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a immunomodulation platform to treat chronic and acute inflammatory disorders. It also provides hematopoietic stem cell based therapies to treat hematologic malignancies; a vocal biomarker technology to monitor and diagnose psychological and physical medical conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate which is in Phase 1 clinical trial to treat lymphedema, and other lymphatic and fibrotic disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has a collaboration with Boehringer Ingelheim to advance immuno-oncology product candidates. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Pharmaceutical Industry Immunology Health Sciences Medication Monoclonal Antibody Gastrointestinal Dysfunction Urology Schizophrenia Nervous System Disorders Biomarker Milk Central Nervous System Disorders Specialty Drugs Neurology Dementia Psychiatry Hematologic Malignancies Hematopoietic Stem Cell Chronic Disease Alzheimer's Choline Chronic Diseases Boehringer Ingelheim Immune Mediated Diseases Inflammatory Disorders Exosome Galectin Cognitive Dysfunction Psychosis Biomarker Technology Kar Xt Lymphedema Parkinson's Diseases Puretech Health

Is PRTC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 63.95
52 Week Low 33.0
Average Volume 1,783
200-Day Moving Average 0.00
50-Day Moving Average 54.38
20-Day Moving Average 54.98
10-Day Moving Average 55.02
Average True Range 3.95
ADX 32.3
+DI 36.93
-DI 19.91
Chandelier Exit (Long, 3 ATRs ) 48.12
Chandelier Exit (Short, 3 ATRs ) 62.35
Upper Bollinger Band 60.57
Lower Bollinger Band 49.40
Percent B (%b) 0.77
BandWidth 20.32
MACD Line 0.18
MACD Signal Line 0.51
MACD Histogram -0.3224
Fundamentals Value
Market Cap 1.66 Billion
Num Shares 28.6 Million
EPS
Price-to-Sales 93.65
Price-to-Book 1.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 65.46
Resistance 3 (R3) 64.63 61.31 64.21
Resistance 2 (R2) 61.31 59.41 61.73 63.80
Resistance 1 (R1) 59.66 58.24 60.49 60.49 63.38
Pivot Point 56.34 56.34 56.76 56.76 56.34
Support 1 (S1) 54.69 54.44 55.52 55.52 52.62
Support 2 (S2) 51.37 53.27 51.79 52.20
Support 3 (S3) 49.72 51.37 51.79
Support 4 (S4) 50.55